Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects research hub

A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)

This study tests a new cell therapy called ADP-A2M4CD8, given alone or with an immunotherapy drug called nivolumab, for women with recurrent ovarian cancer. Researchers want to see if this treatment can shrink tumours and how safe it is for patients whose cancer has returned after previous treatments.